PTC Therapeutics, Inc. (PTCT) News
Filter PTCT News Items
PTCT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PTCT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PTCT News From Around the Web
Below are the latest news stories about PTC THERAPEUTICS INC that investors may wish to consider to help them evaluate PTCT as an investment opportunity.
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PST / 2:15 p.m. EST. |
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich AtaxiaPTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with Friedreich ataxia (FA) to the U.S. Food and Drug Administration (FDA). |
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,725 shares of its common stock and 5,060 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to eight new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. |
UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's DrugUniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment. |
PTC Therapeutics price target raised to $71 from $47 at UBSUBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement with Novartis (NVS) for its Huntington’s Disease program, PTC518, under which PTC will receive $1B at closing and is eligible for up to $1.9B in development, regulatory and sales milestones, the analyst tells investors in a research note. PTC is a high conviction call into 2025, where UBS sees PTC a |
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 BillionNVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug. |
PTCT Stock Soars on Licensing Deal With NVS for Huntington's TherapyPer the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion. |
Novartis and PTC Therapeutics link to develop Huntington’s therapyPTC Therapeutics is set to obtain an upfront payment of $1bn. |
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking ZoneNovartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. |
Sector Update: Health Care Stocks Slipping Late AfternoonHealth care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health |